Table 2.
Prevalence of Stunting at Enrollment and Follow-up in Children With Moderate-to-Severe Diarrhea (MSD) and Children Without MSD During May 2015 to July 2018, by Site and Age
| The Gambia | Mali | Kenya | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Age Group | Children With MSD, n (%) |
Children Without MSD, n (%) |
P a | Children With MSD, n (%) |
Children Without MSD, n (%) |
P a | Children With MSD, n (%) |
Children Without MSD, n (%) |
P a |
| 0–11 Months, n | 512 | 670 | 562 | 665 | 555 | 700 | |||
| ȃStunted at enrollment | 82 (16.0) |
100 (14.9) |
.66 | 52 (9.3) |
59 (8.9) |
.90 | 102 (18.4) |
119 (17.0) |
.57 |
| ȃStunted at follow-up | 128 (25.0) |
150 (22.4) |
.33 | 84 (14.9) |
84 (12.6) |
.27 | 140 (25.2) |
152 (21.7) |
.16 |
| ȃP valueb | <.0001* | <.0001* | <.0001* | .0006* | <.0001* | <.0001* | |||
| 12–23 Months, n | 581 | 715 | 532 | 620 | 505 | 703 | |||
| ȃStunted at enrollment | 161 (27.7) |
215 (30.1) |
.38 | 104 (19.5) |
99 (16.0) |
.13 | 141 (27.9) |
208 (29.6) |
.57 |
| ȃStunted at follow-up | 194 (33.4) |
238 (33.3) |
1.00 | 124 (23.3) |
102 (16.5) |
.004* | 171 (33.9) |
229 (32.6) |
.68 |
| ȃP valueb | <.0001* | .002* | .002* | .75 | <.0001* | .004* | |||
| 24–59 Months, n | 486 | 661 | 448 | 611 | 422 | 631 | |||
| ȃStunted at enrollment | 169 (34.8) |
207 (31.3) |
.24 | 80 (17.9) |
78 (12.8) |
.03* | 112 (26.5) |
185 (29.3) |
.36 |
| ȃStunted at follow-up | 178 (36.6) |
213 (32.2) |
.14 | 78 (17.4) |
77 (12.6) |
.04* | 121 (28.7) |
181 (28.7) |
1.00 |
| ȃP valueb | .16 | .36 | .83 | 1.00 | .066 | .48 | |||
Data are presented as n (%) unless otherwise indicated.
Abbreviation: MSD, moderate-to-severe diarrhea.
Chi-square test of association between stunting status (yes/no) at enrollment and MSD/diarrhea-free status, similarly for stunting status at follow-up.
McNemar's test comparing the proportion of stunting at enrollment to the proportion stunted at follow-up within each MSD/diarrhea-free group.
*Significant, P < .05.